Product Program year 2025 Source: CMS Open Payments

Benlysta

Biological Immunology

NDC 49401-101-01

Open in the dashboard

General payments

$12,916,398

124,306 payments

Research payments

$26,942,531

3,441 payments

Through program year 2025, $12,916,398 in general payments and $26,942,531 in research payments were reported against Benlysta (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $1,744,247 19,905
2025 Research $4,672,583 713
2024 General $1,889,271 19,686
2024 Research $1,972,320 370
2023 General $2,471,850 23,437
2023 Research $2,265,124 373
2022 General $2,545,295 21,762
2022 Research $3,879,305 204
2021 General $2,293,471 19,357
2021 Research $2,197,384 249
2020 General $1,113,411 8,480
2020 Research $4,386,360 781
2019 General $858,854 11,679
2019 Research $7,569,455 751

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $12,916,398 124,306 payments
Top recipients General payments · program year 2025
  1. Irfan Agha Nephrology · Dallas, TX $75,454 4% · 53 payments
  2. Maureen McMahon Rheumatology · Los Angeles, CA $45,046 3% · 23 payments
  3. Leanna Wise Rheumatology · Los Angeles, CA $38,970 2% · 30 payments
  4. Julio Gonzalez-Paoli Rheumatology · Tampa, FL $37,092 2% · 45 payments
  5. Eddie Rodriguez Castro Nephrology · Toa Baja, PR $33,339 2% · 23 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Rheumatology Internal Medicine $1,059,628 64% · 2,059 practitioners
  2. Nephrology Internal Medicine $344,050 21% · 887 practitioners
  3. Internal Medicine $65,090 4% · 248 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $45,987 3% · 499 practitioners
  5. Physician Assistant $44,944 3% · 333 practitioners

The top 5 of 91 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $265,368 15% · 623 recipients
  2. Texas $246,515 14% · 556 recipients
  3. Florida $242,832 14% · 500 recipients
  4. New York $92,070 5% · 251 recipients
  5. Pennsylvania $72,095 4% · 177 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

35,996

Prescriptions dispensed, refills included

Drug cost

$170,650,113

Paid at the pharmacy, in all

Prescribers

1,496

With 11 or more claims of it

Medicare Part D drugs matched to BENLYSTA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Benlysta Belimumab Same name 1,496 35,996 $170,650,113

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jose Rubio Mosquera Rheumatology AL 381 $1,747,267 None on record
Elvin Garcia Rheumatology TX 269 $932,143 None on record
Jeremy Anuntiyo Internal Medicine CA 251 $1,173,948 $59
Victoria Katz Rheumatology NY 247 $867,720 $10
Gerald Ho Rheumatology CA 237 $745,584 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to BENLYSTA
Billing code Providers Services Paid by Medicare
Injection, belimumab, 10 mg J0490 41 199,234 $7,714,783

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

124,306 general · 3,441 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record